ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

7 years ago

ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07

Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of Antares Pharma, Inc. (the
Company) was held on June 7, 2017. The following proposals, all
of which were set forth in the Companys definitive proxy
statement on Schedule 14A, as filed with the Securities and
Exchange Commission on April 27, 2017, were voted on at the
Annual Meeting. Set forth below are the final voting results for
each of the proposals submitted to a vote of the shareholders.

1.	The nominees for election as Class I directors of the Companys Board of Directors, each for a three year term, were elected based upon the following vote:

Nominee	For	Withheld	Broker Non-Votes
1. Leonard Jacob, M.D., Ph.D.	57,598,619	2,508,020	62,962,858
2. Marvin Samson	57,791,101	2,315,538	62,962,858

2.	The proposal to approve, on a non-binding, advisory basis, the compensation of our named executive officers (say-on-pay), was approved based upon the following votes:


For	Against	Abstain	Broker Non-Votes
56,041,921	3,024,055	1,040,663	62,962,858

3.	The proposal to approve, on a non-binding, advisory basis, the frequency of the vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers, was approved based upon the following vote:

One Year	Two Years	Three Years	Abstain
52,352,033	1,430,600	4,953,399	1,370,607

4.The proposal to ratify the appointment of KPMG LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December 31, 2017 was approved based upon the
following votes:

For	Against	Abstain
122,446,956	516,347	106,194

About ANTARES PHARMA, INC. (NASDAQ:ATRS)
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.